ProCEPT Cut Its 2026 Procedure Outlook-Why Q4 Profitability Is the Real Test

The guide cut lowered the ceiling, but revenue guidance held

PROCEPT now expects 54,000–56,000 2026 U.S. procedures, down from the prior path. That matters because procedure volume has been one of the clearest signals that the business is expanding. Still, the more important context is that the company kept full-year 2026 revenue guidance of $390 million to $410 million. The debate is no longer just about a lower procedure ceiling; it is about whether revenue can stay supported even with softer usage at the margin.

Q2 reinforced that mix. Revenue rose to $94.5 million, up 19%, while the net loss widened. More relevant to the current debate, management lifted its full-year operating-expense outlook to $355 million–$360 million. Higher spending raises the bar when a key volume target is trimmed. In that setup, the real test is whether PROCEPT can still reach positive adjusted EBITDA in the fourth quarter. If it does, the outlook cut will look more like a reset than a broken story. If not, investors may start treating the lower procedure range as the new baseline.

The repeat-sales engine still looks intact, but utilization is uneven

Procedures and handpieces still track closely

The basic model is straightforward: install systems, generate cases, then sell handpieces as those cases happen. In Q1, U.S. users completed approximately 12,200 U.S. procedures, and handpiece sales were about 95% of procedures. That close relationship suggests the repeat-sales component was still working, even as field inventory normalized.

Why the procedure outlook was reduced

The revision was not driven by broad weakness across the installed base. Management said the slowdown was concentrated in legacy AquaBeam accounts, while HYDROS accounts had procedures significantly higher per HYDROS account. In other words, older sites were underperforming, but newer HYDROS-driven sites were still generating stronger activity.

Q2 illustrates that split. PROCEPT completed more than 13,100 U.S. procedures during the quarter, up about 21%, yet management still described that result as below expectations. The company responded by keeping its revenue target while trimming the procedure ceiling to better reflect weaker usage at the tail end of the base. That looks less dramatic in context because revenue was still being supported by pricing and replacement-system sales.

What matters most from here

The current setup can be tracked with a short scoreboard. Investors should watch whether PROCEPT can:

• build on more than 13,100 U.S. procedures during the quarter and produce a steadier case flow through year-end,
• support the existing 54,000–56,000 2026 U.S. procedures outlook, and
• still reach positive adjusted EBITDA in the fourth quarter despite the higher full-year operating-expense outlook.

If HYDROS performance keeps outperforming legacy accounts and higher spending begins to show up in better utilization, the outlook cut is more likely to be viewed as a calibration. If older-account usage continues to weigh on the base without improving, the same cut is easier to read as the start of a softer trend.